About Eisai
Eisai is a publicly listed company based in Tokyo (Japan) founded in 1941. Drugs for oncology and neurological disorders are developed by Eisai. The company has 10,920 employees. Eisai has completed 3 acquisitions, including AkaRx, MGI Pharma and Morphotek. Its chief executive, as recorded, is Haruo Naito. Its website eisai.com draws about 74 thousand monthly visits. Its focus areas include Diversified Pharmaceuticals and Drugs. Its legal entity is EISAI (THAILAND) MARKETING.
Company details
Eisai was founded in 1941 in Tokyo, Japan, and operates in the pharmaceutical sector. Focus is placed on developing treatments for oncology and neurological conditions. Key products include rabeprazole for gastroesophageal reflux disease, risedronic acid for osteoporosis, palonosetron for chemotherapy-induced nausea, donepezil for Alzheimers disease, rufinamide for seizures in Lennox-Gastaut syndrome, lorcaserin for obesity, and dalteparin for deep vein thrombosis and pulmonary embolism. Global operations support drug development and distribution.
- Headquarters Tokyo, Japan
- Employees 10,920
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website eisai.com/index.html
- Social LinkedIn X Facebook
- Legal Name Eisai Co., Ltd.
Funding Insights of Eisai
- Total Rounds 2
- Last Round Grant — $947,650
- First Round $1.25M
(Aug 2007)
- Investors Count 1
All 2 funding rounds of Eisai with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in Eisai
Eisai has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Eisai
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eisai
312 people are tracked at Eisai (174 in leadership, 8 in board & advisors, 130 in team); the tracked headcount is 10,920.
| Name | Role | Group |
|---|---|---|
Haruo Naito | CEO | Leadership |
Cathy Candelario | Associate Director Of Benefits & Wellbeing | Leadership |
Alexis Campanile | Manager, Human Resources Business Partner | Leadership |
Tom Dannenbrink | Senior Director Commercial Effectiveness & Planning | Leadership |
Neriman Botas | Executive Vice President Human Resources | Leadership |
Yasushi Okada | COO | Leadership |
Masatomi Akana | SVP, Chief Government Relations Officer Global Value & Access | Leadership |
Keisuke Naito | VP, Chief Digital Officer Head of Consumer Experience Transformation HQs Deputy President, Eisai Japan | Leadership |
Tatsuyuki Yasuno | SVP, President, Americas Region President, Eisai Inc. | Leadership |
Akiko Nakahama | VP & Head, Medicine Development Center | Leadership |
Takashi Owa | SVP, Oncology Business Group, Chief Discovery Officer, Oncology Business Group-Japan & Asia Medical | Leadership |
Sayoko Sasaki | VP, Chief IR Officer Stakeholder Communications | Leadership |
Gary Tvrdik | Head, Supply Chain Finance | Leadership |
Dara Kuller | Director, Market Access | Leadership |
Brian Hatch | Director Of Information Technology - Infrastructure And Hosting Operations | Leadership |
Carol Rockett | Senior Director Medical Affairs | Leadership |
Teruyuki Masaka | VP & Chief HR Officer | Leadership |
Alana Eiseman | Associate Director, Corporate Advocacy | Leadership |
Sumit Rawal | Director, Clinical Pharmacology And Translational Medicine | Leadership |
Daren Holaday | Associate Director Federal Markets | Leadership |
292 more people are available in the full profile.
Complete people profiles for Eisai
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Eisai
Eisai is a publicly listed company on the TSE with ticker symbol 4523 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Sep 1961
- Listed onTSE: 4523
- Listed entityEisai Co., Ltd.
- Exchange sectorHealth technology
- ISINJP3160400002
- Share price4,692.00 JPY (+0.79% on the day) · 2026-10-14
- Market capitalisation1,311,935,208,435.00 JPY
- Price to earnings31.3
- EPS (diluted, trailing year)150.08 JPY
- Dividend yield3.44%
- Volume (last session)1,318,100
Financials of Eisai
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 825.38B JPY | 38.56B JPY | 89.89B JPY |
| 2024 | 789.40B JPY | 46.43B JPY | 89.15B JPY |
| 2023 | 741.75B JPY | 42.41B JPY | 86.15B JPY |
| 2022 | 744.40B JPY | 55.43B JPY | 79.20B JPY |
| 2021 | 756.23B JPY | 47.95B JPY | 98.02B JPY |
Detailed financial statements for Eisai
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eisai
Eisai has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include AkaRx, MGI Pharma and Morphotek.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Limited information available | akarx.com | Paramus, United States | 2005 | Jan 2010 | $255M | |
Oncology and acute care pharmaceuticals are developed and commercialized. | mgipharma.com | Woodcliff Lake, United States | 1979 | Dec 2007 | •••• | |
Monoclonal antibodies against cancer, inflammatory and infectious diseases. | morphotek.com | Exton, United States | 2000 | Mar 2007 | $325M |
Complete acquisition details for Eisai
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Eisai
7 dated milestones of Eisai across 70 years, from founding to its latest funding, stage changes and deals.
- Founded Eisai is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Morphotek.
- Funding First funding round of $1.3M.
- Acquisition Acquires MGI Pharma.
- Acquisition Acquires AkaRx.
- Funding Latest funding round, Grant, of $948K.
Web traffic of Eisai
The website of Eisai (eisai.com) receives about 74.5K visits a month and ranks #534,857 among all websites worldwide, #552 in Biotechnology and Pharmaceuticals.
- Monthly visits74.5K
▲ 12.8% vs previous month
- Unique visitors30.5K
per month
- Global rank#534,857
among all websites
- Category rank#552
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit1.9
- Average visit31 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Eisai. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ds-pharma.com | 100% | View details | |||
| novartis.com | 96% | 948.8K | #58,822 | View details | |
| daiichisankyo.com | 91% | 72.3K | #682,883 | View details | |
| endo.com | 87% | 10K | #2,323,439 | View details | |
chiesiusa.com | chiesiusa.com | 85% | #1,397,563 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Eisai
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eisai
Complete news archive for Eisai
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eisai
Eisai was founded in 1941 and raised its 1st funding round 66 years after it was founded.
Eisai is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Haruo Naito is the CEO of Eisai, as recorded in our data.
Eisai has 10,920 employees.
Annual revenue of Eisai is $5.17B as on Mar 31, 2026.
Eisai was founded in 1941 in Tokyo, Japan, and operates in the pharmaceutical sector. Focus is placed on developing treatments for oncology and neurological conditions. Key products include rabeprazole for gastroesophageal reflux disease, risedronic acid for osteoporosis, palonosetron for chemotherapy-induced nausea, donepezil for Alzheimers disease, rufinamide for seizures in Lennox-Gastaut syndrome, lorcaserin for obesity, and dalteparin for deep vein thrombosis and pulmonary embolism. Global operations support drug development and distribution.
Yes, Eisai is publicly traded on TSE under the ticker symbol 4523.
Eisai has made 3 acquisitions, including AkaRx, MGI Pharma, and Morphotek.
Eisai has 1 investor. Key investors include HHS.
Eisai operates through Eisai (Thailand) Marketing.